Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Optibrium’s StarDrop now powered by OpenEye Scientific’s cheminformatics toolkits

Optibrium and OpenEye Scientific, leading providers of software and services for drug discovery, today announced that StarDrop, Optibrium’s software for small molecule design, optimization and data analysis, is now powered by OpenEye Scientific’s cheminformatics toolkits.

From Optibrium Ltd. 13 May 2020

Sanford director receives major grant to advance broad-spectrum antivirals for respiratory diseases

Sanford Burnham Prebys Medical Discovery Institute is pleased to announce that Sumit Chanda, Ph.D., has received a $10.2 million, four-year grant from the Department of Defense to develop and advance broad-spectrum antivirals for respiratory diseases.

12 May 2020

Regeneron and CCPM collaborate to advance human genetics, precision medicine

Regeneron Pharmaceuticals, Inc. and the Colorado Center for Personalized Medicine at the University of Colorado Anschutz Medical Campus today announced a large-scale research collaboration designed to advance the field of human genetics and precision medicine through the sharing of 450,000 DNA samples and corresponding health records from de-identified, consented patient participants in the expansive UCHealth system.

11 May 2020

GCS centers support research to fight against global COVID-19 pandemic

In December 2019, the world learned of a new and deadly pathogen. News coming out of Wuhan, China confirmed public health experts' worst fears--a novel coronavirus appeared to have jumped from animals to humans.

11 May 2020

AI VIVO seeks pharma, biotech collaboration partners to advance drug candidates for COVID-19

AI VIVO has announced that it is seeking pharma and biotech collaboration partners to progress therapeutic candidates for COVID-19.

11 May 2020

New breakthrough in chemistry could accelerate drug development

Scientists have successfully developed a new technique to reliably grow crystals of organic soluble molecules from nanoscale droplets, unlocking the potential of accelerated new drug development.

8 May 2020

A comprehensive review on therapeutic properties of plants

Nature is an amazing source for food, shelter, clothing and medicine. An impressive number of modern drugs are isolated from many sources such as plants, animals and microbes.

8 May 2020

Study investigates potential use of metal catalysts to create drug discovery platform

The use of metals in drug delivery could offer major benefits, including allowing for lower dosages of a medication to achieve therapeutic effects.

6 May 2020

Quantum machine learning may lead to possible treatments for COVID-19

Quantum machine learning, an emerging field that combines machine learning and quantum physics, is the focus of research to discover possible treatments for COVID-19, according to Penn State researchers led by Swaroop Ghosh, the Joseph R. and Janice M. Monkowski Career Development Assistant Professor of Electrical Engineering and Computer Science and Engineering.

5 May 2020

Scripps professor receives Research Program Award for advancing RNA-targeting medicines

In recognition of his high-impact work advancing the field of RNA-targeting medicines, the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, has awarded Scripps Research Chemistry Professor Matthew Disney, PhD, a prestigious Research Program Award, to aid Disney's development of treatments for incurable diseases such as Alzheimer's, Parkinson's, ALS and frontotemporal dementia.

4 May 2020

Improving Automated NMR Integration Through Deep Learning

In this interview, Data Scientist Federico Paruzzo discusses how Bruker has used deep learning to develop the new command, and how it compares to other approaches available.

From Bruker BioSpin Group 30 Apr 2020

Astellas and Insilico collaborate on new AI technology to develop new drug candidates

Insilico Medicine has announced that it has entered into a research collaboration agreement with Astellas Pharma Inc. to utilize Insilico Medicine's novel generative artificial intelligence technology aimed at accelerating development of candidates against a conventionally challenging target family.

28 Apr 2020

Researchers harness the power of AI to accelerate drug discovery

As the COVID-19 crisis continues to develop, researchers around the world are attempting to find the most effective treatment to combat the poorly understood virus behind this disease.

27 Apr 2020

Investigational drug may hold benefit for patients with lung and ovarian cancers

In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.

27 Apr 2020

Researchers re-purpose cancer-fighting artificial antibodies for COVID-19

Researcher Paula Bates, John Trent, and Don Miller developed a therapeutic drug that could potentially block the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the COVID-19 pandemic. Their research was initially aimed at helping patients suffering from multiple types of cancer.

27 Apr 2020

Researchers report new imaging method that creates fast, inexpensive 3D images

Researchers at the University of Houston last year reported a new imaging method capable of producing fast and inexpensive three-dimensional images, offering the potential to more easily track the progress of conditions such as Alzheimer's disease and cancer at the cellular level.

24 Apr 2020

Scientists are developing synthetic COVID-19 antibody to treat sick patients

A team of researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with GenScript, is developing a synthetic antibody to SARS-CoV-2, the virus that causes coronavirus disease (COVID-19). This antibody is intended to block the virus from entering human lung cells, and would be another potential treatment option for COVID-19.

24 Apr 2020

Sygnature Discovery loans key equipment to support UK Government’s COVID-19 testing strategy

Sygnature Group is supporting the Government’s COVID-19 testing strategy with the loan of a key piece of equipment. The machine, a Tecan Freedom EVO 100, will be used to help automate and accelerate the analysis of samples at the first of the UK Government’s new Lighthouse Labs in Milton Keynes.

24 Apr 2020

UAB to join international effort to test drugs for COVID-19

The University of Alabama at Birmingham will join an international effort coordinated by Scripps Research to test drugs for COVID-19.

24 Apr 2020

A protein discovery could pave way to better treatments for obesity

A USC-led international team of scientists has found the precise shape of a key player in human metabolism, which could lead the way to better treatments for obesity and other metabolic disease.

23 Apr 2020